Dr. Abulrob recently participated in a webcast to thescientific research community, launching ART's new in vivo optical imager,Optix MX2. During this webcast, Dr. Abulrob provided experimental examples fromhis own research on the capabilities of Optix's analytical software package,OptiView. Dr. Abulrob's team has been using the Optix system for newapplications of optical imaging and fluorescence lifetime, in addition to theevaluation of investigative drugs in stroke, Alzheimer's disease and braincancer.
"The scientific exchange and collaboration between theNRC-IBS and ART has already proven beneficial for advancing both scientificdiscovery and technology development in the emerging field of molecularimaging. This collaboration agreement with the NRC-IBS creates newopportunities to respond to the challenges faced by our customers in drugdevelopment. Now, by contributing to enable novel Optix applications, the NRCwill play an important role in advancing our plan to develop solutions for ourclients and help them shorten the drug development cycle," said Mr. SebastienGignac, ART's president and CEO.
